About Regenevia

Advancing Epigenetic Innovation with Scientific Rigor and Vision

REGENEVIA BIO is an innovation-driven research company focused on advancing the frontiers of epigenetics, cellular reprogramming, and longevity-oriented biological systems.

Our Mission

Founded on the conviction that aging and biological decline are complex, multi-layered processes, Regenevia approaches innovation through rigorous science, strategic thinking, and long-term responsibility.

Our work is grounded in the study of how cellular identity, functional resilience, and adaptive capacity can be understood, guided, and optimized over time. We believe that the future of human health lies not in treating symptoms, but in understanding and restoring the fundamental regulatory mechanisms that govern biological aging.

Scientific exploration at Regenevia is not treated as a collection of experiments, but as a coherent, evolving research architecture.
Research

Our Vision

Regenevia envisions a future in which epigenetic science becomes a foundational tool for understanding and supporting long-term human vitality. Rather than pursuing short-term or reductionist solutions, we focus on building robust scientific platforms capable of evolving alongside emerging knowledge, technologies, and societal needs.

Depth Over Speed

We prioritize deep understanding of biological systems over rapid but superficial interventions, ensuring lasting scientific value.

Systems-Level Thinking

We favor comprehensive, systems-level understanding over isolated interventions, recognizing the interconnected nature of biological processes.

Protected Innovation

Every discovery is structured within a robust intellectual property framework, ensuring scalable and strategically valuable assets.

Long-Term Impact

We measure success not by short-term claims but by meaningful, sustained contributions to the science of human longevity.

Our Scientific Philosophy

At the core of Regenevia lies a commitment to methodological rigor and intellectual integrity. We operate at the intersection of epigenetics, systems biology, and advanced cellular modeling, with a particular focus on controlled and partial cellular reprogramming strategies.

Biological Complexity

Deep respect for the intricate regulatory networks that govern cellular behavior and tissue homeostasis.

Precision & Control

Epigenetic modulation guided by precise, reproducible protocols designed for safety and efficacy.

Research Integrity

Clear separation between experimental research and clinical application, with continuous validation and critical assessment.

Innovation with Structure

Innovation at Regenevia is deliberately structured. From early-stage concepts to advanced research platforms, intellectual property considerations are integrated into every phase of development. This ensures that discoveries mature into protected, scalable, and strategically valuable assets.

Proprietary Platforms

Epigenetic and reprogramming platforms developed in-house with full IP protection across multiple jurisdictions.

Translational Research

Research designed from inception for industrial collaboration and real-world application.

Strategic Partnerships

Collaborations aligned with scientific depth, integrity, and shared long-term vision.

A Responsible Approach to Longevity

Regenevia approaches longevity science with caution, responsibility, and realism. We reject overstated promises and simplistic narratives in favor of scientifically grounded, ethically aware exploration.

Our work is conducted within a strictly research-oriented context and is guided by the principle that meaningful progress in longevity requires patience, interdisciplinary collaboration, transparency, and respect for regulatory and ethical boundaries.

As epigenetic science continues to evolve, Regenevia is committed to remaining a thoughtful, reliable, and forward-looking contributor to the field.

Regenevia is not defined by a single technology or product, but by a long-term commitment to scientific excellence, structured innovation, and responsible exploration of biological potential.

Leadership

Dr. Giorgio S.C. Linchi

Founder & President — Long Life Genetics / REGENEVIA LLC

Dr.ssa Katia Memoli

Anti-Aging Center

Dr. Marco Felli

Head of Research

Dr.ssa Elvira Di Nucci

Head of Research

Dr.ssa Loredana Felli

Coordination & Logistics

Dr. Sergio Rosa

Logistics

Mr. Alex De Martino

Logistics & Communications — London Office

The Lynch Group

Regenevia and GenAtlantica Life Sciences, together with REGENEVIA SPACE, are part of the Lynch Group, an advanced scientific research consortium.

Born from an idea conceived in 2016 with the establishment of Long Life Genetics in London, we are convinced that transcending the limits of our planet and significantly extending human life are two inseparable aspects of evolution, representing the next step for our species.

Explore Group Vision